English

CHINA PHARMA HOLDINGS, INC.

EDGAR

CHPI Quarterly report (10-Q) · filed 2026-08-14

Annual consolidated revenue for 2025: about USD 4.144M, using the latest reported figures. The previous period, 2024, was about USD 4.529M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

948 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 948340 USD Source

Operating margin

-150.98%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -1431845 USD Source
Revenue: 948340 USD Source

Operating cash flow

-32.8 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -88120 USD Source
Operating Cash Flow: -55292 USD Source

Cash and cash equivalents: 300 thousand USD 2026-06-30 Source
Exact value

300000 USD
Long-term debt including current maturities: 4.33 million USD 2021-09-30 Source
Exact value

4332809 USD
Shares outstanding: 40.5 million shares 2026-06-30 Source
Exact value

40522002 shares

Reported share-count change

1,142.24% · 37.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3262022 shares · 2025-06-30· Source
40522002 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

3.91 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 756217 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 4144268 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 2918271 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 983536 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 948340 USD · 2026-04-01 – 2026-06-30 Source

Net income

-4.44 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -651482 USD · 2025-07-01 – 2025-09-30 Source
Net income: -3187556 USD · 2025-01-01 – 2025-12-31 Source
Net income: -2000000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -1143148 USD · 2026-01-01 – 2026-03-31 Source
Net income: -1458123 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2020-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-8.5%

Prior period

USD 4.53 million

2024-01-01 – 2024-12-31
Current period

USD 4.14 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4144268 − 4528929 = -384661 USD

4528929 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4144268 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Year-over-year change in Revenue: -384661 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4144268 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#753606 Filing: 000121390026038521 Input fundies:Revenue: 4528929 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#753950 Filing: 000121390026038521
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 1.55 million

Prior period

−USD 4.74 million

2024-01-01 – 2024-12-31
Current period

−USD 3.19 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-3187556 − -4736365 = 1548809 USD

-4736365 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-3187556 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Year-over-year change in Net income: 1548809 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -3187556 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#1142320 Filing: 000121390026038521 Input fundies:NetIncome: -4736365 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#1142678 Filing: 000121390026038521
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 554,324

Prior period

−USD 406,063

2024-01-01 – 2024-12-31
Current period

USD 148,261

2025-01-01 – 2025-12-31

Exact inputs and evidence

148261 − -406063 = 554324 USD

-406063 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
148261 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Year-over-year change in Operating cash flow: 554324 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 148261 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#825627 Filing: 000121390026038521 Input fundies:OperatingCashFlow: -406063 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#826079 Filing: 000121390026038521
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+54.4%

Prior period

USD 38,411

2024-01-01 – 2024-12-31
Current period

USD 59,324

2025-01-01 – 2025-12-31

Exact inputs and evidence

59324 − 38411 = 20913 USD

38411 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
59324 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Year-over-year change in Capital expenditure: 20913 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 59324 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#827405 Filing: 000121390026038521 Input fundies:CapitalExpenditure: 38411 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#827730 Filing: 000121390026038521
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 4.14 million 100% of revenue
Cost of revenue USD 4.28 million 103% of revenue
Operating expenses USD 3.11 million 75% of revenue
Operating income −USD 3.24 million −78% of revenue
Tax, interest and other Derived −USD 51,522 −1.2% of revenue
Net income −USD 3.19 million −77% of revenue

Cash

Operating cash flow USD 148,261 3.6% of revenue
Capital expenditure USD 59,324 1.4% of revenue
Free cash flow Derived USD 88,937 2.1% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 152% of revenue.
2017 Operating loss: operating costs were 241% of revenue.
2018 Operating loss: operating costs were 185% of revenue.
2019 Operating loss: operating costs were 287% of revenue.
2020 Operating loss: operating costs were 124% of revenue.
2021 Operating loss: operating costs were 130% of revenue.
2022 Operating loss: operating costs were 144% of revenue.
2023 Operating loss: operating costs were 139% of revenue.
2024 Operating loss: operating costs were 201% of revenue.
2025 Operating loss: operating costs were 178% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	15570514	23725981 Derived	-8155467	1027157 Derived	-9182624	2702304 Derived	Source 2016-01-01 – 2016-12-31: 15570514 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -8155467 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -9182624 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 2895708 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 193404 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	13212314	31892328 Derived	-18680014	597551 Derived	-19277565	704737 Derived	Source 2017-01-01 – 2017-12-31: 13212314 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -18680014 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -19277565 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 841216 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 136479 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	12330687	22778101 Derived	-10447414	302753 Derived	-10750167	1830975 Derived	Source 2018-01-01 – 2018-12-31: 12330687 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -10447414 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -10750167 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 1882120 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 51145 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	10923936	31331789 Derived	-20407853	294191 Derived	-20702044	472309 Derived	Source 2019-01-01 – 2019-12-31: 10923936 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -20407853 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -20702044 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 608312 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 136003 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	10866449	13444742 Derived	-2578293	288484 Derived	-2866777	-909567 Derived	Source 2020-01-01 – 2020-12-31: 10866449 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -2578293 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -2866777 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -42260 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 867307 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	9641925	12502435 Derived	-2860510	538966 Derived	-3399476	-687893 Derived	Source 2021-01-01 – 2021-12-31: 9641925 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -2860510 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -3399476 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -249838 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 438055 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	8104092	11653069 Derived	-3548977	423864 Derived	-3972841	-811509 Derived	Source 2022-01-01 – 2022-12-31: 8104092 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -3548977 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -3972841 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -409545 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 401964 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	7011299	9763119 Derived	-2751820	326998 Derived	-3078818	-711203 Derived	Source 2023-01-01 – 2023-12-31: 7011299 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -2751820 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -3078818 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -699686 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 11517 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	4528929	9117795 Derived	-4588866	147499 Derived	-4736365	-444474 Derived	Source 2024-01-01 – 2024-12-31: 4528929 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -4588866 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -4736365 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -406063 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 38411 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	4144268	7383346 Derived	-3239078	-51522 Derived	-3187556	88937 Derived	Source 2025-01-01 – 2025-12-31: 4144268 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -3239078 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -3187556 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 148261 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 59324 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 4.1M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	15570514	Revenue: 15570514 Open source
20172017-12-31	Revenue	13212314	Revenue: 13212314 Open source
20182018-12-31	Revenue	12330687	Revenue: 12330687 Open source
20192019-12-31	Revenue	10923936	Revenue: 10923936 Open source
20202020-12-31	Revenue	10866449	Revenue: 10866449 Open source
20212021-12-31	Revenue	9641925	Revenue: 9641925 Open source
20222022-12-31	Revenue	8104092	Revenue: 8104092 Open source
20232023-12-31	Revenue	7011299	Revenue: 7011299 Open source
20242024-12-31	Revenue	4528929	Revenue: 4528929 Open source
20252025-12-31	Revenue	4144268	Revenue: 4144268 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-8.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-23.5%	Revenue: 15570514 Open source Revenue: 20351630 Open source
20172017-12-31	Year over year	-15.1%	Revenue: 13212314 Open source Revenue: 15570514 Open source
20182018-12-31	Year over year	-6.7%	Revenue: 12330687 Open source Revenue: 13212314 Open source
20192019-12-31	Year over year	-11.4%	Revenue: 10923936 Open source Revenue: 12330687 Open source
20202020-12-31	Year over year	-0.5%	Revenue: 10866449 Open source Revenue: 10923936 Open source
20212021-12-31	Year over year	-11.3%	Revenue: 9641925 Open source Revenue: 10866449 Open source
20222022-12-31	Year over year	-15.9%	Revenue: 8104092 Open source Revenue: 9641925 Open source
20232023-12-31	Year over year	-13.5%	Revenue: 7011299 Open source Revenue: 8104092 Open source
20242024-12-31	Year over year	-35.4%	Revenue: 4528929 Open source Revenue: 7011299 Open source
20252025-12-31	Year over year	-8.5%	Revenue: 4144268 Open source Revenue: 4528929 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -78.2% 2025

Net margin -76.9% 2025

Free cash flow margin 2.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-52.4%	Operating Income: -8155467 Open source Revenue: 15570514 Open source
20172017-12-31	Operating margin	-141.4%	Operating Income: -18680014 Open source Revenue: 13212314 Open source
20182018-12-31	Operating margin	-84.7%	Operating Income: -10447414 Open source Revenue: 12330687 Open source
20192019-12-31	Operating margin	-186.8%	Operating Income: -20407853 Open source Revenue: 10923936 Open source
20202020-12-31	Operating margin	-23.7%	Operating Income: -2578293 Open source Revenue: 10866449 Open source
20212021-12-31	Operating margin	-29.7%	Operating Income: -2860510 Open source Revenue: 9641925 Open source
20222022-12-31	Operating margin	-43.8%	Operating Income: -3548977 Open source Revenue: 8104092 Open source
20232023-12-31	Operating margin	-39.2%	Operating Income: -2751820 Open source Revenue: 7011299 Open source
20242024-12-31	Operating margin	-101.3%	Operating Income: -4588866 Open source Revenue: 4528929 Open source
20252025-12-31	Operating margin	-78.2%	Operating Income: -3239078 Open source Revenue: 4144268 Open source
20162016-12-31	Net margin	-59%	Net Income: -9182624 Open source Revenue: 15570514 Open source
20172017-12-31	Net margin	-145.9%	Net Income: -19277565 Open source Revenue: 13212314 Open source
20182018-12-31	Net margin	-87.2%	Net Income: -10750167 Open source Revenue: 12330687 Open source
20192019-12-31	Net margin	-189.5%	Net Income: -20702044 Open source Revenue: 10923936 Open source
20202020-12-31	Net margin	-26.4%	Net Income: -2866777 Open source Revenue: 10866449 Open source
20212021-12-31	Net margin	-35.3%	Net Income: -3399476 Open source Revenue: 9641925 Open source
20222022-12-31	Net margin	-49%	Net Income: -3972841 Open source Revenue: 8104092 Open source
20232023-12-31	Net margin	-43.9%	Net Income: -3078818 Open source Revenue: 7011299 Open source
20242024-12-31	Net margin	-104.6%	Net Income: -4736365 Open source Revenue: 4528929 Open source
20252025-12-31	Net margin	-76.9%	Net Income: -3187556 Open source Revenue: 4144268 Open source
20162016-12-31	Free cash flow margin	17.4%	Revenue: 15570514 Open source Operating Cash Flow: 2895708 Open source Capital Expenditure: 193404 Open source
20172017-12-31	Free cash flow margin	5.3%	Revenue: 13212314 Open source Operating Cash Flow: 841216 Open source Capital Expenditure: 136479 Open source
20182018-12-31	Free cash flow margin	14.8%	Revenue: 12330687 Open source Operating Cash Flow: 1882120 Open source Capital Expenditure: 51145 Open source
20192019-12-31	Free cash flow margin	4.3%	Revenue: 10923936 Open source Operating Cash Flow: 608312 Open source Capital Expenditure: 136003 Open source
20202020-12-31	Free cash flow margin	-8.4%	Revenue: 10866449 Open source Operating Cash Flow: -42260 Open source Capital Expenditure: 867307 Open source
20212021-12-31	Free cash flow margin	-7.1%	Revenue: 9641925 Open source Operating Cash Flow: -249838 Open source Capital Expenditure: 438055 Open source
20222022-12-31	Free cash flow margin	-10%	Revenue: 8104092 Open source Operating Cash Flow: -409545 Open source Capital Expenditure: 401964 Open source
20232023-12-31	Free cash flow margin	-10.1%	Revenue: 7011299 Open source Operating Cash Flow: -699686 Open source Capital Expenditure: 11517 Open source
20242024-12-31	Free cash flow margin	-9.8%	Revenue: 4528929 Open source Operating Cash Flow: -406063 Open source Capital Expenditure: 38411 Open source
20252025-12-31	Free cash flow margin	2.1%	Revenue: 4144268 Open source Operating Cash Flow: 148261 Open source Capital Expenditure: 59324 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 148.3K 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	2895708	Operating Cash Flow: 2895708 Open source
20172017-12-31	Operating cash flow	841216	Operating Cash Flow: 841216 Open source
20182018-12-31	Operating cash flow	1882120	Operating Cash Flow: 1882120 Open source
20192019-12-31	Operating cash flow	608312	Operating Cash Flow: 608312 Open source
20202020-12-31	Operating cash flow	-42260	Operating Cash Flow: -42260 Open source
20212021-12-31	Operating cash flow	-249838	Operating Cash Flow: -249838 Open source
20222022-12-31	Operating cash flow	-409545	Operating Cash Flow: -409545 Open source
20232023-12-31	Operating cash flow	-699686	Operating Cash Flow: -699686 Open source
20242024-12-31	Operating cash flow	-406063	Operating Cash Flow: -406063 Open source
20252025-12-31	Operating cash flow	148261	Operating Cash Flow: 148261 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 88.9K 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	2702304	Operating Cash Flow: 2895708 Open source Capital Expenditure: 193404 Open source
20172017-12-31	Free cash flow	704737	Operating Cash Flow: 841216 Open source Capital Expenditure: 136479 Open source
20182018-12-31	Free cash flow	1830975	Operating Cash Flow: 1882120 Open source Capital Expenditure: 51145 Open source
20192019-12-31	Free cash flow	472309	Operating Cash Flow: 608312 Open source Capital Expenditure: 136003 Open source
20202020-12-31	Free cash flow	-909567	Operating Cash Flow: -42260 Open source Capital Expenditure: 867307 Open source
20212021-12-31	Free cash flow	-687893	Operating Cash Flow: -249838 Open source Capital Expenditure: 438055 Open source
20222022-12-31	Free cash flow	-811509	Operating Cash Flow: -409545 Open source Capital Expenditure: 401964 Open source
20232023-12-31	Free cash flow	-711203	Operating Cash Flow: -699686 Open source Capital Expenditure: 11517 Open source
20242024-12-31	Free cash flow	-444474	Operating Cash Flow: -406063 Open source Capital Expenditure: 38411 Open source
20252025-12-31	Free cash flow	88937	Operating Cash Flow: 148261 Open source Capital Expenditure: 59324 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

26.6% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	25%	Total Liabilities: 19611006 Open source Total Assets: 78520140 Open source
20172017-12-31	Liabilities / assets	28.2%	Total Liabilities: 16881598 Open source Total Assets: 59952900 Open source
20182018-12-31	Liabilities / assets	33.4%	Total Liabilities: 15178550 Open source Total Assets: 45377325 Open source
20192019-12-31	Liabilities / assets	58.5%	Total Liabilities: 12997621 Open source Total Assets: 22235222 Open source
20202020-12-31	Liabilities / assets	62.1%	Total Liabilities: 13113460 Open source Total Assets: 21117991 Open source
20212021-12-31	Liabilities / assets	73.4%	Total Liabilities: 16631886 Open source Total Assets: 22649767 Open source
20222022-12-31	Liabilities / assets	75.9%	Total Liabilities: 13494145 Open source Total Assets: 17784143 Open source
20232023-12-31	Liabilities / assets	54.7%	Total Liabilities: 9014579 Open source Total Assets: 16469200 Open source
20242024-12-31	Liabilities / assets	48%	Total Liabilities: 7139620 Open source Total Assets: 14887524 Open source
20252025-12-31	Liabilities / assets	26.6%	Total Liabilities: 8259712 Open source Total Assets: 30999464 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.32× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	1.68×	Current Assets: 17519951 Open source Current Liabilities: 10397730 Open source
20172017-12-31	Current assets / current liabilities	1.33×	Current Assets: 12290087 Open source Current Liabilities: 9227132 Open source
20182018-12-31	Current assets / current liabilities	0.87×	Current Assets: 8746916 Open source Current Liabilities: 10051456 Open source
20192019-12-31	Current assets / current liabilities	0.56×	Current Assets: 5579005 Open source Current Liabilities: 10045308 Open source
20202020-12-31	Current assets / current liabilities	0.47×	Current Assets: 5321958 Open source Current Liabilities: 11403676 Open source
20212021-12-31	Current assets / current liabilities	0.86×	Current Assets: 9093409 Open source Current Liabilities: 10513298 Open source
20222022-12-31	Current assets / current liabilities	0.47×	Current Assets: 5964546 Open source Current Liabilities: 12739447 Open source
20232023-12-31	Current assets / current liabilities	0.88×	Current Assets: 5996933 Open source Current Liabilities: 6820664 Open source
20242024-12-31	Current assets / current liabilities	0.65×	Current Assets: 3270389 Open source Current Liabilities: 5017288 Open source
20252025-12-31	Current assets / current liabilities	0.32×	Current Assets: 2346407 Open source Current Liabilities: 7400359 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 9.18 million Exact value Exact value: -9182624 USD 2016-01-01 – 2016-12-31: -9182624 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2016-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -9182624 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9182624 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/cphi-20171231.xml#66883 Filing: 000121390018003895 The citation records this snapshot. The page link may show a newer release later.	USD 2.9 million Exact value Exact value: 2895708 USD 2016-01-01 – 2016-12-31: 2895708 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2016-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: 2895708 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2895708 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/cphi-20171231.xml#92154 Filing: 000121390018003895 The citation records this snapshot. The page link may show a newer release later.	USD 193,404 Exact value Exact value: 193404 USD 2016-01-01 – 2016-12-31: 193404 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2016-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 193404 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 193404 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/cphi-20171231.xml#76159 Filing: 000121390018003895 The citation records this snapshot. The page link may show a newer release later.	USD 2.7 million Calculation and evidence 2895708 − 193404 USD Exact free cash flow: 2702304 USD 2016-01-01 – 2016-12-31: 2895708 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 193404 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2016-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: 2702304 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 2895708 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/cphi-20171231.xml#92154 Filing: 000121390018003895 Input fundies:CapitalExpenditure: 193404 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/cphi-20171231.xml#76159 Filing: 000121390018003895 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 19.28 million Exact value Exact value: -19277565 USD 2017-01-01 – 2017-12-31: -19277565 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2017-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -19277565 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19277565 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/cphi-20180930.xml#192483 Filing: 000121390019005094 The citation records this snapshot. The page link may show a newer release later.	USD 841,216 Exact value Exact value: 841216 USD 2017-01-01 – 2017-12-31: 841216 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2017-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: 841216 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 841216 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/cphi-20180930.xml#73238 Filing: 000121390019005094 The citation records this snapshot. The page link may show a newer release later.	USD 136,479 Exact value Exact value: 136479 USD 2017-01-01 – 2017-12-31: 136479 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2017-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 136479 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 136479 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/cphi-20180930.xml#77298 Filing: 000121390019005094 The citation records this snapshot. The page link may show a newer release later.	USD 704,737 Calculation and evidence 841216 − 136479 USD Exact free cash flow: 704737 USD 2017-01-01 – 2017-12-31: 841216 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 136479 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2017-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: 704737 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 841216 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/cphi-20180930.xml#73238 Filing: 000121390019005094 Input fundies:CapitalExpenditure: 136479 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/cphi-20180930.xml#77298 Filing: 000121390019005094 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 10.75 million Exact value Exact value: -10750167 USD 2018-01-01 – 2018-12-31: -10750167 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2018-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -10750167 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10750167 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/cphi-20191231.xml#83404 Filing: 000121390020008020 The citation records this snapshot. The page link may show a newer release later.	USD 1.88 million Exact value Exact value: 1882120 USD 2018-01-01 – 2018-12-31: 1882120 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2018-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: 1882120 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1882120 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/cphi-20191231.xml#59995 Filing: 000121390020008020 The citation records this snapshot. The page link may show a newer release later.	USD 51,145 Exact value Exact value: 51145 USD 2018-01-01 – 2018-12-31: 51145 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2018-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 51145 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51145 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/cphi-20191231.xml#100760 Filing: 000121390020008020 The citation records this snapshot. The page link may show a newer release later.	USD 1.83 million Calculation and evidence 1882120 − 51145 USD Exact free cash flow: 1830975 USD 2018-01-01 – 2018-12-31: 1882120 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 51145 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2018-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: 1830975 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1882120 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/cphi-20191231.xml#59995 Filing: 000121390020008020 Input fundies:CapitalExpenditure: 51145 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/cphi-20191231.xml#100760 Filing: 000121390020008020 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 20.7 million Exact value Exact value: -20702044 USD 2019-01-01 – 2019-12-31: -20702044 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2019-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -20702044 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20702044 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390021017981/cphi-20201231.xml#70933 Filing: 000121390021017981 The citation records this snapshot. The page link may show a newer release later.	USD 608,312 Exact value Exact value: 608312 USD 2019-01-01 – 2019-12-31: 608312 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2019-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: 608312 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 608312 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390021017981/cphi-20201231.xml#122813 Filing: 000121390021017981 The citation records this snapshot. The page link may show a newer release later.	USD 136,003 Exact value Exact value: 136003 USD 2019-01-01 – 2019-12-31: 136003 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2019-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 136003 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 136003 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390021017981/cphi-20201231.xml#420827 Filing: 000121390021017981 The citation records this snapshot. The page link may show a newer release later.	USD 472,309 Calculation and evidence 608312 − 136003 USD Exact free cash flow: 472309 USD 2019-01-01 – 2019-12-31: 608312 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 136003 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2019-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: 472309 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 608312 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390021017981/cphi-20201231.xml#122813 Filing: 000121390021017981 Input fundies:CapitalExpenditure: 136003 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390021017981/cphi-20201231.xml#420827 Filing: 000121390021017981 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 2.87 million Exact value Exact value: -2866777 USD 2020-01-01 – 2020-12-31: -2866777 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2020-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -2866777 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2866777 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021_chinapharma.htm#740322 Filing: 000121390022016151 The citation records this snapshot. The page link may show a newer release later.	−USD 42,260 Exact value Exact value: -42260 USD 2020-01-01 – 2020-12-31: -42260 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2020-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: -42260 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42260 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021_chinapharma.htm#750901 Filing: 000121390022016151 The citation records this snapshot. The page link may show a newer release later.	USD 867,307 Exact value Exact value: 867307 USD 2020-01-01 – 2020-12-31: 867307 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2020-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 867307 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 867307 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021_chinapharma.htm#752737 Filing: 000121390022016151 The citation records this snapshot. The page link may show a newer release later.	−USD 909,567 Calculation and evidence -42260 − 867307 USD Exact free cash flow: -909567 USD 2020-01-01 – 2020-12-31: -42260 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 867307 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2020-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: -909567 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42260 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021_chinapharma.htm#750901 Filing: 000121390022016151 Input fundies:CapitalExpenditure: 867307 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021_chinapharma.htm#752737 Filing: 000121390022016151 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 3.4 million Exact value Exact value: -3399476 USD 2021-01-01 – 2021-12-31: -3399476 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2021-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -3399476 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3399476 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#769657 Filing: 000121390023024710 The citation records this snapshot. The page link may show a newer release later.	−USD 249,838 Exact value Exact value: -249838 USD 2021-01-01 – 2021-12-31: -249838 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2021-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: -249838 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -249838 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#784132 Filing: 000121390023024710 The citation records this snapshot. The page link may show a newer release later.	USD 438,055 Exact value Exact value: 438055 USD 2021-01-01 – 2021-12-31: 438055 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2021-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 438055 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 438055 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#787048 Filing: 000121390023024710 The citation records this snapshot. The page link may show a newer release later.	−USD 687,893 Calculation and evidence -249838 − 438055 USD Exact free cash flow: -687893 USD 2021-01-01 – 2021-12-31: -249838 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 438055 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2021-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: -687893 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -249838 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#784132 Filing: 000121390023024710 Input fundies:CapitalExpenditure: 438055 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#787048 Filing: 000121390023024710 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 3.97 million Exact value Exact value: -3972841 USD 2022-01-01 – 2022-12-31: -3972841 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2022-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -3972841 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3972841 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390024028731/ea0202772-10k_china.htm#789464 Filing: 000121390024028731 The citation records this snapshot. The page link may show a newer release later.	−USD 409,545 Exact value Exact value: -409545 USD 2022-01-01 – 2022-12-31: -409545 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2022-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: -409545 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -409545 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390024028731/ea0202772-10k_china.htm#799719 Filing: 000121390024028731 The citation records this snapshot. The page link may show a newer release later.	USD 401,964 Exact value Exact value: 401964 USD 2022-01-01 – 2022-12-31: 401964 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2022-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 401964 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 401964 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#786462 Filing: 000121390023024710 The citation records this snapshot. The page link may show a newer release later.	−USD 811,509 Calculation and evidence -409545 − 401964 USD Exact free cash flow: -811509 USD 2022-01-01 – 2022-12-31: -409545 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 401964 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2022-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: -811509 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -409545 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390024028731/ea0202772-10k_china.htm#799719 Filing: 000121390024028731 Input fundies:CapitalExpenditure: 401964 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024710/f10k2022_chinapharma.htm#786462 Filing: 000121390023024710 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 3.08 million Exact value Exact value: -3078818 USD 2023-01-01 – 2023-12-31: -3078818 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2023-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -3078818 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3078818 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390025026280/ea0234263-10k_chinapharm.htm#797608 Filing: 000121390025026280 The citation records this snapshot. The page link may show a newer release later.	−USD 699,686 Exact value Exact value: -699686 USD 2023-01-01 – 2023-12-31: -699686 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2023-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: -699686 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -699686 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390025026280/ea0234263-10k_chinapharm.htm#807941 Filing: 000121390025026280 The citation records this snapshot. The page link may show a newer release later.	USD 11,517 Exact value Exact value: 11517 USD 2023-01-01 – 2023-12-31: 11517 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2023-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 11517 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11517 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390025026280/ea0234263-10k_chinapharm.htm#809611 Filing: 000121390025026280 The citation records this snapshot. The page link may show a newer release later.	−USD 711,203 Calculation and evidence -699686 − 11517 USD Exact free cash flow: -711203 USD 2023-01-01 – 2023-12-31: -699686 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 11517 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2023-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: -711203 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -699686 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390025026280/ea0234263-10k_chinapharm.htm#807941 Filing: 000121390025026280 Input fundies:CapitalExpenditure: 11517 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390025026280/ea0234263-10k_chinapharm.htm#809611 Filing: 000121390025026280 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 4.74 million Exact value Exact value: -4736365 USD 2024-01-01 – 2024-12-31: -4736365 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2024-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -4736365 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4736365 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#1142678 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.	−USD 406,063 Exact value Exact value: -406063 USD 2024-01-01 – 2024-12-31: -406063 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2024-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: -406063 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -406063 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#826079 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.	USD 38,411 Exact value Exact value: 38411 USD 2024-01-01 – 2024-12-31: 38411 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2024-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 38411 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 38411 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#827730 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.	−USD 444,474 Calculation and evidence -406063 − 38411 USD Exact free cash flow: -444474 USD 2024-01-01 – 2024-12-31: -406063 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 38411 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2024-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: -444474 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -406063 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#826079 Filing: 000121390026038521 Input fundies:CapitalExpenditure: 38411 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#827730 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 3.19 million Exact value Exact value: -3187556 USD 2025-01-01 – 2025-12-31: -3187556 USD Inspect Net Income Open source Share or cite Citation for Net Income · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Net Income: -3187556 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3187556 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#1142320 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.	USD 148,261 Exact value Exact value: 148261 USD 2025-01-01 – 2025-12-31: 148261 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Operating Cash Flow: 148261 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 148261 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#825627 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.	USD 59,324 Exact value Exact value: 59324 USD 2025-01-01 – 2025-12-31: 59324 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Capital Expenditure: 59324 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 59324 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#827405 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.	USD 88,937 Calculation and evidence 148261 − 59324 USD Exact free cash flow: 88937 USD 2025-01-01 – 2025-12-31: 148261 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 59324 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CHINA PHARMA HOLDINGS, INC. · 2025-12-31 CHINA PHARMA HOLDINGS, INC. (edgar:1106644) Free cash flow: 88937 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:20:03Z Snapshot: cff24dbdcb8e76ce8416dd4500c72cbecab71c632035101f7ec7027e424e3db0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1106644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 148261 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#825627 Filing: 000121390026038521 Input fundies:CapitalExpenditure: 59324 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm#827405 Filing: 000121390026038521 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

142 filings · 4,758 latest values · 4,758 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001106644, 1106644, CHPI, CPHI, cphi, edgar:1106644

Also known as CHINA PHARMA HOLDINGS, INC., China Pharma Holdings, Inc., KILKENNY ACQUISITION CORP, SOFTSTONE INC, SOFTSTONE INC /DE/, TS ELECTRONICS INC

CHINA PHARMA HOLDINGS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation